26 / 34
The dilemma of choosing the 2nd line
treatment in RCC: Points to consider
1. Grande E,
et al
.
World J Clin Oncol
2017;8(2):100–5; 2. Eggers H,
et al
.
J Kidney Cancer VHL
2017;4:8–15.; 3. Signorovitch J,
et al
.
Curr Med Res Op
2014;30:2343–53.
Sunitinib/
pazopanib
?
Tolerability to 1st line treatment
1
Time of clinical benefit to 1st line
1
Tumour growth rate after progression to 1st line
1
Symptoms/burden of disease
1
Sites of metastasis
1
MSKCC/Heng’s prognosis
2
Age/comorbidities/ECOG PS
2,3